Lipitor's Peak Sales Before Patent Expiry
Lipitor (atorvastatin), made by Pfizer, hit peak annual sales of $12.9 billion in 2010, its final full year under patent protection. The main U.S. composition-of-matter patent expired November 30, 2011, after pediatric exclusivity extensions.[1][2]
Revenue Drop in the First Year Post-Expiry
Sales fell 29% to $9.2 billion globally in 2011 as generic competition began in the U.S. from December 2011. By 2012, revenue plunged another 42% to $5.4 billion, reflecting widespread generic entry from Ranbaxy, Watson, Mylan, and others.[1][3]
| Year | Global Revenue ($B) | YoY Change |
|------|---------------------|------------|
| 2010 | 12.9 | - |
| 2011 | 9.2 | -29% |
| 2012 | 5.4 | -42% |
| 2013 | 3.8 | -30% |
| 2014 | 2.6 | -32% |
Why Sales Declined So Sharply
Generics captured over 80% of U.S. prescriptions within months, priced at 80-90% less than Lipitor. Pfizer's authorized generic via Ranbaxy slowed some erosion but couldn't halt it. International markets saw slower generic entry due to varying patents, propping up some revenue longer.[2][4]
Long-Term Revenue Decline and Stabilization
By 2015, sales dropped below $2 billion annually, hitting $1.4 billion in 2016. Revenue stabilized around $1-1.5 billion through 2020 from brand-loyal patients, emerging markets, and combo formulations like Caduet. Pfizer discontinued U.S. promotion in 2012 but kept manufacturing.[1][3]
How Generic Entry Happened Despite Pfizer's Defenses
Pfizer settled Hatch-Waxman litigation with generics firms in 2008, delaying U.S. entry until late 2011. A 180-day exclusivity for Ranbaxy was forfeited in 2011 over manufacturing issues, accelerating competition. No major patent challenges overturned expiry.[2][5]
Impact on Pfizer's Overall Business
Lipitor's cliff contributed to a $30 billion revenue drop from 2011-2013, offset by drugs like Prevnar and Eliquis. It highlighted "patent cliff" risks for blockbusters.[1][4]
Sources
[1]: Pfizer Annual Reports 2010-2016
[2]: FDA Orange Book Patent Listings for Atorvastatin
[3]: IMS Health/QuintilesIMS Sales Data via FiercePharma
[4]: DrugPatentWatch.com - Lipitor Patent Expiry Timeline
[5]: FTC Report on Lipitor Settlements